Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Global Smart Insulin or Glucose Responsive Insulin Market (2022 to 2027) - Featuring AstraZeneca, Biocon and Dongbao Enterprise Among Others


DUBLIN, Aug. 16, 2022 /PRNewswire/ -- The "Global Smart Insulin or Glucose Responsive Insulin Market (2022-2027) by Drug, Delivery Devices, Disease, Type, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Smart Insulin or Glucose Responsive Insulin Market is estimated to be USD 3.12 Bn in 2022 and is expected to reach USD 5.19 Bn by 2027, growing at a CAGR of 10.7%.

Market dynamics are forces that impact the prices and behaviors of the Global Smart Insulin or Glucose Responsive Insulin Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors.

There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Adocia, AstraZeneca, B. Braun Melsungen, Becton, Dickinson and Company, Biocon, Biodel, Bioton, Dongbao Enterprise Group, Eli Lilly and Company, GSK, etc.

Countries Studied

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Smart Insulin or Glucose Responsive Insulin Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification.

The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics
4.1 Drivers
4.1.1 Growing Prevalence of Diabetes Among the Population
4.1.2 Increasing Incidence of Geriatric and Obese Population
4.1.3 Rapid Development in Insulin Delivery Systems, Drug
4.2 Restraints
4.2.1 High Cost Associated with Insulin Drugs
4.3 Opportunities
4.3.1 New Regulations for Insulin Biosimilars and Rising Investments in R&D
4.3.2 High Potential of Insulin Drug in Emerging Economies
4.4 Challenges
4.4.1 Strict Regulatory Norms for the Approval of Product

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis

6 Global Smart Insulin or Glucose Responsive Insulin Market, By Drug
6.1 Introduction
6.2 Biologic
6.3 Biosimilar

7 Global Smart Insulin or Glucose Responsive Insulin Market, By Delivery Devices
7.1 Introduction
7.2 Smart Insulin Pens
7.3 Smart Insulin Pumps

8 Global Smart Insulin or Glucose Responsive Insulin Market, By Disease
8.1 Introduction
8.2 Type I Diabetes
8.3 Type II Diabetes

9 Global Smart Insulin or Glucose Responsive Insulin Market, By Type
9.1 Introduction
9.2 Rapid-acting Insulin
9.3 Short-acting Insulin
9.4 Intermediate-acting Insulin
9.5 Long-acting Insulin
9.6 Pre-mixed Insulin

10 Americas' Smart Insulin or Glucose Responsive Insulin Market
10.1 Introduction
10.2 Argentina
10.3 Brazil
10.4 Canada
10.5 Chile
10.6 Colombia
10.7 Mexico
10.8 Peru
10.9 United States
10.10 Rest of Americas

11 Europe's Smart Insulin or Glucose Responsive Insulin Market
11.1 Introduction
11.2 Austria
11.3 Belgium
11.4 Denmark
11.5 Finland
11.6 France
11.7 Germany
11.8 Italy
11.9 Netherlands
11.10 Norway
11.11 Poland
11.12 Russia
11.13 Spain
11.14 Sweden
11.15 Switzerland
11.16 United Kingdom
11.17 Rest of Europe

12 Middle East and Africa's Smart Insulin or Glucose Responsive Insulin Market
12.1 Introduction
12.2 Egypt
12.3 Israel
12.4 Qatar
12.5 Saudi Arabia
12.6 South Africa
12.7 United Arab Emirates
12.8 Rest of MEA

13 APAC's Smart Insulin or Glucose Responsive Insulin Market
13.1 Introduction
13.2 Australia
13.3 Bangladesh
13.4 China
13.5 India
13.6 Indonesia
13.7 Japan
13.8 Malaysia
13.9 Philippines
13.10 Singapore
13.11 South Korea
13.12 Sri Lanka
13.13 Thailand
13.14 Taiwan
13.15 Rest of Asia-Pacific

14 Competitive Landscape
14.1 Competitive Quadrant
14.2 Market Share Analysis
14.3 Strategic Initiatives
14.3.1 M&A and Investments
14.3.2 Partnerships and Collaborations
14.3.3 Product Developments and Improvements

15 Company Profiles
15.1 Adocia
15.2 AstraZeneca
15.3 B. Braun Melsungen
15.4 Becton, Dickinson and Company
15.5 Biocon
15.6 Biodel
15.7 Bioton
15.8 Dongbao Enterprise Group
15.9 Eli Lilly and Company
15.10 GSK
15.11 Johnson & Johnson
15.12 Julphar
15.13 MannKind
15.14 Medtronic
15.15 Merck & Co.
15.16 Novartis International
15.17 Novo Nordisk
15.18 Oramed Pharmaceuticals
15.19 Pfizer
15.20 Piramal Healthcare
15.21 Sanofi
15.22 Teijin
15.23 Tonghua Dongbao Pharmaceutical
15.24 US Vitamins
15.25 Wockhardt
15.26 Ypsomed Holding

16 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/c7dzoz

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 18:50
In a new video released today, Mark A. Smith, CEO and Executive Chairman of NioCorp Developments Ltd. ("NioCorp" or the "Company") and Dean Kehler, CEO and Co-Chairman of GX Acquisition Corp. II ("GXII") , discuss the recently announced definitive...

at 18:45
The global consumer healthcare market size is expected to grow by USD 123.78 billion, accelerating at a CAGR of 5.66% between 2021 and 2026. According to the report, the market structure is fragmented due to the presence of several large and small...

at 18:33
The warehousing and storage market size is expected to grow by USD 387.49 billion during 2021-2026, at a CAGR of 6.53% during the forecast period, according to Technavio....

at 18:15
The "Ocular Implants Market by Product (IOLs, corneal implants, glaucoma implants, and ocular prostheses) and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to Technavio's...

at 18:05
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the closing of an underwritten public offering of: (i)...

at 17:05
The Veladero gold mine has reached its 17th anniversary since first gold in October 2005 and the company remains committed to improving the asset, building on strong partnerships with the local community, and exploring to increase its resources.     ...



News published on 16 august 2022 at 11:15 and distributed by: